| Field . | Research questions . | Potential approaches . |
|---|---|---|
| Pathogenesis | What are the sub-populations involved in the pathogenesis of sicca syndrome in SSc patients, including adaptive immunity (B cells, T cells), innate immunity (macrophages), glandular epithelial cells and fibroblasts? | Identification of new subpopulations using new omics technologies such as single cell RNA sequencing for SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc, pSS and overlap of pSS with SSc patients in terms of major contributing cell sub-populations, suggesting that therapeutic targets may differ between these sub-groups of patients? | ||
| Diagnosis and severity assessment | What is the contribution of US evaluation to the diagnosis and assessment of major salivary glands in SSc patients with sicca symptoms? | Comparison of US parameters with histological findings in SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc-related sicca symptoms and overlap with pSS in terms of US evaluation and are these differences associated with different histological patterns in minor salivary glands? | ||
| Clinical assesment | Are PROs currently used in patients with pSS adapted for sicca syndrome in SSc? | Evaluation of the psychometric properties of PROs assessing sicca symptoms in observational cohorts of patients with SSc |
| Are new PROs needed? | ||
| Therapeutics | Impact of new therapeutics on sicca symptoms in patients with SSc (anti-fibrotic drug such as nintedanib, B cell targeting therapies including rituximab or belimumab) | Inclusion of sicca symptoms as exploratory outcomes in future RCTs |
| Field . | Research questions . | Potential approaches . |
|---|---|---|
| Pathogenesis | What are the sub-populations involved in the pathogenesis of sicca syndrome in SSc patients, including adaptive immunity (B cells, T cells), innate immunity (macrophages), glandular epithelial cells and fibroblasts? | Identification of new subpopulations using new omics technologies such as single cell RNA sequencing for SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc, pSS and overlap of pSS with SSc patients in terms of major contributing cell sub-populations, suggesting that therapeutic targets may differ between these sub-groups of patients? | ||
| Diagnosis and severity assessment | What is the contribution of US evaluation to the diagnosis and assessment of major salivary glands in SSc patients with sicca symptoms? | Comparison of US parameters with histological findings in SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc-related sicca symptoms and overlap with pSS in terms of US evaluation and are these differences associated with different histological patterns in minor salivary glands? | ||
| Clinical assesment | Are PROs currently used in patients with pSS adapted for sicca syndrome in SSc? | Evaluation of the psychometric properties of PROs assessing sicca symptoms in observational cohorts of patients with SSc |
| Are new PROs needed? | ||
| Therapeutics | Impact of new therapeutics on sicca symptoms in patients with SSc (anti-fibrotic drug such as nintedanib, B cell targeting therapies including rituximab or belimumab) | Inclusion of sicca symptoms as exploratory outcomes in future RCTs |
PROs: patient reported outcomes; pSS: primary Sjögren’s syndrome; RCT: randomized controlled trial.
| Field . | Research questions . | Potential approaches . |
|---|---|---|
| Pathogenesis | What are the sub-populations involved in the pathogenesis of sicca syndrome in SSc patients, including adaptive immunity (B cells, T cells), innate immunity (macrophages), glandular epithelial cells and fibroblasts? | Identification of new subpopulations using new omics technologies such as single cell RNA sequencing for SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc, pSS and overlap of pSS with SSc patients in terms of major contributing cell sub-populations, suggesting that therapeutic targets may differ between these sub-groups of patients? | ||
| Diagnosis and severity assessment | What is the contribution of US evaluation to the diagnosis and assessment of major salivary glands in SSc patients with sicca symptoms? | Comparison of US parameters with histological findings in SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc-related sicca symptoms and overlap with pSS in terms of US evaluation and are these differences associated with different histological patterns in minor salivary glands? | ||
| Clinical assesment | Are PROs currently used in patients with pSS adapted for sicca syndrome in SSc? | Evaluation of the psychometric properties of PROs assessing sicca symptoms in observational cohorts of patients with SSc |
| Are new PROs needed? | ||
| Therapeutics | Impact of new therapeutics on sicca symptoms in patients with SSc (anti-fibrotic drug such as nintedanib, B cell targeting therapies including rituximab or belimumab) | Inclusion of sicca symptoms as exploratory outcomes in future RCTs |
| Field . | Research questions . | Potential approaches . |
|---|---|---|
| Pathogenesis | What are the sub-populations involved in the pathogenesis of sicca syndrome in SSc patients, including adaptive immunity (B cells, T cells), innate immunity (macrophages), glandular epithelial cells and fibroblasts? | Identification of new subpopulations using new omics technologies such as single cell RNA sequencing for SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc, pSS and overlap of pSS with SSc patients in terms of major contributing cell sub-populations, suggesting that therapeutic targets may differ between these sub-groups of patients? | ||
| Diagnosis and severity assessment | What is the contribution of US evaluation to the diagnosis and assessment of major salivary glands in SSc patients with sicca symptoms? | Comparison of US parameters with histological findings in SSc, pSS and overlap of pSS with SSc patients |
| Are there differences between SSc-related sicca symptoms and overlap with pSS in terms of US evaluation and are these differences associated with different histological patterns in minor salivary glands? | ||
| Clinical assesment | Are PROs currently used in patients with pSS adapted for sicca syndrome in SSc? | Evaluation of the psychometric properties of PROs assessing sicca symptoms in observational cohorts of patients with SSc |
| Are new PROs needed? | ||
| Therapeutics | Impact of new therapeutics on sicca symptoms in patients with SSc (anti-fibrotic drug such as nintedanib, B cell targeting therapies including rituximab or belimumab) | Inclusion of sicca symptoms as exploratory outcomes in future RCTs |
PROs: patient reported outcomes; pSS: primary Sjögren’s syndrome; RCT: randomized controlled trial.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
